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The biomarker and causal roles of 
homoarginine in the development 
of cardiometabolic diseases: an 
observational and Mendelian 
randomization analysis
Ilkka Seppälä  1, Niku Oksala1,2, Antti Jula3, Antti J. Kangas4,5, Pasi Soininen4,5, Nina Hutri-
Kähönen6, Winfried März7,8,9, Andreas Meinitzer9, Markus Juonala10,11, Mika Kähönen12, Olli T. 
Raitakari10,13 & Terho Lehtimäki1
High L-homoarginine (hArg) levels are directly associated with several risk factors for cardiometabolic 
diseases whereas low levels predict increased mortality in prospective studies. The biomarker role of 
hArg in young adults remains unknown. To study the predictive value of hArg in the development of 
cardiometabolic risk factors and diseases, we utilized data on high-pressure liquid chromatography-
measured hArg, cardiovascular risk factors, ultrasound markers of preclinical atherosclerosis and type 
2 diabetes from the population-based Young Finns Study involving 2,106 young adults (54.6% females, 
aged 24–39). We used a Mendelian randomization approach involving tens to hundreds of thousands of 
individuals to test causal associations. In our 10-year follow-up analysis, hArg served as an independent 
predictor for future hyperglycaemia (OR 1.31, 95% CI 1.06–1.63) and abdominal obesity (OR 1.60, 95% 
1.14–2.30) in men and type 2 diabetes in women (OR 1.55, 95% CI 1.02–2.41). The MR analysis revealed 
no evidence of causal associations between serum hArg and any of the studied cardiometabolic 
outcomes. In conclusion, lifetime exposure to higher levels of circulating hArg does not seem to alter 
cardiometabolic disease risk. Whether hArg could be used as a biomarker for identification of individuals 
at risk developing cardiometabolic abnormalities merits further investigation.
Accumulating evidence indicates that low levels of serum non-proteinogenic amino acid L-homoarginine (hArg) 
are associated with an increased risk of death from cardiovascular diseases, including heart failure, sudden car-
diac death and fatal strokes, in various patient populations1–6. The association of hArg with adverse cardiovas-
cular outcomes also appears to hold true in a population-based cohort of older adults7 as well as a multi-ethnic 
United States population8. On the other hand, in cross-sectional analyses of these population samples, hArg 
was positively associated with several cardiovascular risk factors including hypertension, obesity, dysglycaemia, 
insulin resistance and dyslipidaemia, referring to the possibility that hArg could also play a causal role in the 
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development of cardiometabolic diseases. Interestingly, recent experimental data indicates that hArg promotes 
the calcification of vascular smooth muscle cells9 and may thus indeed have a causal role in the pathogenesis of 
atherosclerosis.
Supplementation with L-arginine (Arg), the primary precursor of nitric oxide (NO), unexpectedly increased 
cardiovascular events and mortality in a small randomized controlled trial (RCT) in patients with acute coronary 
syndrome10. Whether hArg administration in the secondary prevention setting would have the same detrimental 
effects as Arg, or whether increased levels of hArg would reduce the rate of cardiovascular events and mortal-
ity as suggested by most of the prospective studies, is currently not known. However, before any clinical trials 
using hArg supplementation or a pharmacological intervention to modify circulating hArg levels, it is rational to 
conduct an epidemiological investigation of its causality and potential pleiotropic effects, i.e. both adverse and/
or beneficial effects, by using genetically determined hArg to avoid inaccurate conclusions due to the reverse 
causation and residual confounding related to all observational studies. Moreover, because common cardiomet-
abolic diseases such as type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) develop over several 
decades during one’s lifespan before any symptoms or clinical manifestations, any clinical trials on the effects of 
the lifetime exposure to high hArg in primary prevention settings are not feasible in practice.
So far, no prospective studies have been conducted to study the predictive value of circulating hArg levels 
on the development of metabolic abnormalities in early adulthood. As metabolic syndrome (Mets) or a high 
body mass index (BMI) are strong predictors of future T2DM and cardiovascular disease manifestations11, 12, 
we investigated whether hArg levels could predict the incidence of Mets components or obesity (BMI >30 kg/
m2) and high insulin as well as incident T2DM and preclinical atherosclerosis in a population-based prospec-
tive cohort of young adults without clinical cardiovascular diseases. Moreover, we applied quantitative serum 
nuclear magnetic resonance (NMR) metabolomics to study the detailed molecular associations with hArg in 
young men and women. Furthermore, although we have individual-level genome-wide genetic data available 
for the Cardiovascular Risk in Young Finns Study (YFS) participants, we used summary-level data from several 
large-scale meta-analyses of genome-wide association studies involving tens to hundreds of thousands of indi-
viduals available in the public domain to increase the statistical power to detect potentially causal associations 
between hArg and metabolites, cardiometabolic risk factors, T2DM and CAD.
Results
An overview of the study flow, data sources and statistical analyses is illustrated in Fig. 1.
Clinical characteristics and cross-sectional determinants of serum hArg levels in YFS. Baseline 
characteristics of the YFS study subjects are presented in Table 1. To examine the determinants of hArg levels at 
baseline (2001), we performed a multivariate linear regression analysis using a bi-directional step-wise procedure. 
When all cardiometabolic risk factor variables shown in Table 1, along with serum SHBG, were included in the 
same stepwise multivariable linear regression model, hArg was independently and positively associated with 
male sex, BMI, SHBG, triglycerides and LDL cholesterol (Table 2). Inverse associations of hArg were observed 
with daily smoking and age. The overall R2 for hArg was 0.114, suggesting that 11.4% of the variation in hArg 
concentrations was explained by the selected variables. When the three hArg-related SNPs were further added to 
the model selection procedure, the overall R2 statistic increased to a value of 22.4% (n = 1895) while the signifi-
cance of the other explanatory variables remained roughly the same. Prompted by the association with SHBG and 
a detailed metabolic profiling, the association of hArg with different hormonal contraceptive methods in women 
is shown in Figure S1. In women, HArg was positively associated with the use of combined oral contraceptives 
(containing oestrogen), but not with the use of progestin-only contraceptives (Figure S1).
Longitudinal and cross-sectional associations of hArg with 228 serum metabolites in YFS. The 
cross-sectional and longitudinal (6- to 10-year follow-up) associations of baseline hArg with 228 serum metab-
olites are shown in Figures S2–S3. For both sexes, the strong negative association of glycine with hArg per-
sisted over time during 10 years of follow-up. For all subjects, glycine, histidine and tyrosine showed consistent 
associations with hArg at each time point (Figure S3). The cross-sectional associations of hArg with 73 selected 
metabolomics measures adjusted for age, BMI and daily smoking are illustrated separately for men and women in 
Figure S4. In women, more metabolic measures were associated with hArg compared to men, i.e. 33 measures for 
women and 9 for men (P < 0.002). In women, hArg was positively associated with the smallest very-low-density 
lipoprotein (VLDL), small and medium HDL, the triglyceride content of different lipoprotein classes, as well 
as fatty acids, several amino acids and glycoprotein acetyls (GlycA), which is a novel marker of inflammation 
(Figure S4). Indeed, when further adjusting for oral contraceptive use (in women) and serum SHBG (in both 
sexes), these associations were largely reduced to non-significant, except for the positive associations of amino 
acids and docosahexaenoic acid with hArg in women (Fig. 2). For both sexes, glycine showed a strong nega-
tive association with hArg, whereas the negative association of HDL subclasses and hArg was seen only in men 
(Fig. 2). Significant men-specific interactions were observed between hArg and BMI on glucose, valine and satu-
rated fatty acids (%) (Fig. 2).
Longitudinal relations of hArg with incident obesity, Mets components, preclinical atheroscle-
rosis and T2DM in YFS. In our 6- to 10-year follow-up (depending on the endpoints used) in unadjusted 
analyses, hArg was significantly and directly associated with incident obesity (BMI ≥30 kg/m2), abdominal obe-
sity (high waist circumference), hyperglycaemia, high insulin, high-risk carotid intima-media thickness and dis-
tensibility in men, and with incident T2DM in women (Fig. 3). In our 10-year follow-up analysis after further 
adjustments with other cardiovascular risk factors, hArg served as a significant biomarker for future hypergly-
caemia (OR 1.31, 95% CI 1.06–1.63) and abdominal obesity (OR 1.60, 95% 1.14–2.30) in men and predicted 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 1130  | DOI:10.1038/s41598-017-01274-6
T2DM in women (OR 1.55, 95% CI 1.02–2.41) (Fig. 3). Furthermore, in the cross-sectional study (in 2001), for 
both men and women separately, hArg was strongly associated with BMI (for men P = 5.7 × 10−23, for women 
P = 8.9 × 10−8 and for all subjects combined P = 1.4 × 10−26), but not with BMI-adjusted waist circumference, in 
the observational analyses using the YFS data (Fig. 4).
Estimating causal effects of hArg on obesity, lipids and glycaemic traits as well as T2DM and 
CAD. In this part of the study, utilizing summary-level data from different GWAS meta-analyses available in 
the public domain (Fig. 1), no evidence was found that serum hArg was causally associated with any of the stud-
ied obesity traits (BMI or BMI-adjusted waist circumference), glycaemic or lipid traits, or T2DM or CAD (Fig. 4).
Estimating causal effects of hArg on 122 metabolites. We tested the causality of serum hArg on 122 
NMR-based metabolic measures, and the results of these analyses are illustrated in Fig. 5. No evidence was found 
of a causal relationship between hArg and any of the tested 122 metabolites (for all traits, P-value for combined 
causal estimates >0.05). For three metabolites (creatinine, histidine and glycine), heterogeneity in the causal 
Figure 1. Overview of the study design, data sources and statistical analyses.
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estimates was detected due to strong associations with the CPS1 variant and a lack of association or inconsistent 
association with the two other genetic variants (see Table S1).
Discussion
Consistent with the positive cross-sectional association of hArg with BMI in the present and several previous 
studies1, 6, 8, 13, we now also showed that, in our 10-year follow-up analysis after adjustments with other car-
diovascular risk factors, hArg served as a significant biomarker (predictor) for future hyperglycaemia and for 
abdominal obesity in men and incident T2DM in women. On the other hand, our MR analyses using large-scale 
GWAS meta-analysis summary data did not indicate causal roles for hArg in the development of high BMI or 
BMI-adjusted waist circumference, or any other studied clinical or metabolic trait.
In line with several previous population and patient studies1, 6, 8, 13, we observed a strong positive association 
between hArg and BMI in young adults, whereas the causal effects of hArg on BMI and waist circumference were 
absent. The lack of a causal role of circulating hArg in body weight is supported by an experimental study on 
mice and a small clinical trial showing that several-fold elevations of plasma hArg by oral hArg supplementation 
for several weeks did not have any effect on body weight14, 15. Moreover, L-arginine:glycine amidinotransferase 
(AGAT) -deficient mice exhibiting creatine and hArg5 deficiencies were completely protected from diet-induced 
All Men Women
Number of subjects (%) 2106 957 (45.4) 1149 (54.6)
Age (years) 31.7 (5.0) 31.6 (5.0) 31.7 (5.0)
Homoarginine (hArg) 
(µmol/L) 1.85 (0.65) 1.93 (0.61) 1.79 (0.68)
lnhArg (µmol/L) 0.56 (0.34) 0.61 (0.30) 0.52 (0.36)
LDL cholesterol 
(mmol/L) 3.27 (0.84) 3.42 (0.90) 3.14 (0.77)
HDL cholesterol 
(mmol/L) 1.29 (0.31) 1.17 (0.27) 1.39 (0.30)
Triglycerides (mmol/L) 1.26 (0.64) 1.41 (0.70) 1.13 (0.55)
Systolic blood pressure 
(mmHg) 117 (13) 121 (12) 113 (12)
Diastolic blood pressure 
(mmHg) 72 (11) 73 (11) 69 (10)
C-reactive protein 
(mg/L) 1.9 (4.0) 1.5 (3.4) 2.1 (4.4)
Glucose (mmol/L) 5.1 (0.85) 5.2 (0.93) 4.9 (0.75)
Insulin (IU/L) 7.7 (5.7) 7.6 (5.8) 7.8 (5.7)
Body mass index (kg/m2) 25.0 (4.4) 25.6 (4.1) 24.4 (4.5)
Waist circumference 
(cm) 84 (12) 90 (11) 79 (11)
Daily smokers (%) 520 (24.7) 288 (30.1) 232 (20.2)
Family history of CAD 
(%) 281 (13.3) 123 (12.9) 158 (13.8)
Table 1. Baseline descriptive data for the YFS cohort in 2001. Statistics are mean (SD) or n (%); lnhArg is 
natural log-transformed. CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein.
Explanatory variable β 95% CI P-value
Male sex 0.14 [0.10, 0.17] 4.1 × 10−13
Body mass index (kg/m2) 0.014 [0.0093, 0.018] 1.2 × 10−9
Daily smoking −0.089 [−0.12, −0.056] 1.3 × 10−7
Age (years) −0.0067 [−0.0097, −0.0038] 7.8 × 10−6
lnSHBG (nmol/L) 0.061 [0.032, 0.089] 3.2 × 10−5
lnTriglycerides (mmol/L) 0.045 [0.019, 0.072] 8.2 × 10−4
LDL cholesterol (mmol/L) 0.022 [0.0045, 0.040] 0.014
lnCRP (mg/L) 0.016 [0.0023, 0.029] 0.021
Table 2. Cross-sectional stepwise multivariable linear regression modelling for homoarginine (hArg) 
(n = 2057). Statistics: In the bi-directional stepwise regression modelling applied, serum hArg was used 
as a dependent variable and all the variables shown in Table 1 and lnSHBG as explanatory variables. Those 
variables that were selected by Akaike’s information criterion (AIC) using the stepAIC R function with the 
default settings and had a p-value < 0.05 are shown above. HArg, SHBG, triglycerides and CRP were natural 
log-transformed. For the continuous variables, β (95% CI) are shown for each 1‐unit change in the variable. 
Abbreviations: SHBG, sex hormone-binding globulin; LDL, low-density lipoprotein; CRP, C-reactive protein.
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obesity and metabolic syndrome, whereas oral creatine supplementation resulted in a complete normalisation 
of the body weight and composition of these animals16, suggesting that the effect of AGAT deficiency on BMI 
is hArg-independent. Therefore, it is possible that hArg is a biomarker of AGAT activity and creatine synthesis 
and that higher creatine levels predispose to weight gain, as suggested by the mouse model. This hypothesis is 
supported by our result showing that hArg has some predictive value for the development of abdominal obesity 
during a 10-year follow-up in young men despite careful adjustment for various baseline risk factors, including 
BMI. Concordantly, no change in plasma or tissue hArg concentrations was observed in a small study of patients 
undergoing bariatric surgery despite dramatic weight loss, suggesting that there is no causal effect of BMI on hArg 
levels17. Furthermore, the strong inverse association of baseline hArg and 10-year glycine suggests that hArg has 
some predictive value for creatine synthesis via AGAT (Figure S5) at least 10 years ahead of time. Taken together, 
hArg endogenously synthesized by AGAT might be an excellent marker of systemic creatine synthesis, explaining 
the positive cross-sectional association of hArg with BMI in large population and patient cohorts.
We observed a longitudinal association between baseline hArg levels and 10-year incident hyperglycaemia 
and a positive interaction between baseline hArg and BMI on NMR-based fasting serum glucose in young men. 
However, cross-sectional associations between hArg and fasting glucose were absent in both men and women, in 
line with the lack of causal effects on glycaemic traits in individuals without T2DM. In contrast, hArg was inde-
pendently associated with fasting glucose in older adults13. Moreover, in an RCT on oral hArg supplementation 
lasting 4 weeks in 20 young volunteers, a moderate increase in plasma glucose in comparison to placebo was 
observed15. Compared to a 7-fold increase in hArg plasma levels after supplementation with 125 mg hArg once 
Figure 2. Sex-specific cross-sectional associations of baseline hArg with 73 NMR-based serum metabolites, 
adjusted for age, body mass index (BMI), daily smoking, serum SHBG and oral contraceptive use (in women). 
The analyses were conducted for 867 men and 1097 women. Squares indicate men, and circles represent women. 
Open and closed symbols indicate P ≥ 0.002 and P < 0.002, respectively. Sex differences with P < 0.002 are 
marked by asterisks. BMI interactions with P < 0.002 are marked by the plus or minus sign, depending on the 
direction of the estimated interaction effect.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 1130  | DOI:10.1038/s41598-017-01274-6
daily, the hArg-associated lead GATM variant used in the MR analyses showed a relatively small per allele effect 
of ~0.25 µmol/L (or ~14% increase from the mean value of 1.85 µmol/L). Therefore, the possible effect of hArg on 
blood glucose is likely seen at much higher concentrations of hArg than what is normally present in the blood, in 
line with the tightly regulated glucose homeostasis in humans without overt T2DM. A 16-week oral hArg supple-
mentation resulted in a 6-fold increase in plasma hArg, as well as increased insulin secretion and reduced blood 
glucose in mice on a high-fat diet but not in mice on a normal diet14. This contrasts with a moderate increase in 
blood glucose in the RCT, probably due to the differences in glucose metabolism between mice and humans.
In concordance with several previous studies8, 13, we observed an independent negative association between 
daily smoking and circulating hArg levels, while the molecular underpinnings of this association remain elusive. 
In contrast to some studies on older adults from general and patient populations6, 13, we observed no associations 
between baseline hArg and incident arterial hypertension during a 10-year follow-up, or baseline diastolic or 
systolic blood pressure in young adults. We were unable to study the causality of lifelong exposure to hArg on 
blood pressure due to the lack of publicly available complete summary statistics on the hArg-associated SNPs, 
and further MR studies are thus warranted to address whether there is any causal effect of circulating hArg on 
blood pressure in humans. However, the RCT on hArg supplementation in young volunteers did not detect any 
differences in diastolic or systolic blood pressure between hArg and placebo after a 4-week supplementation15.
Baseline hArg was positively associated with incident T2DM especially in women, although the association 
was attenuated after adjusting for cardiometabolic risk factors and the use of oral contraceptives. A causal effect of 
hArg on T2DM was absent, suggesting that lifelong exposure to higher circulating hArg levels does not increase 
Figure 3. Sex-specific prospective (observational) associations of baseline hArg (in 2001) and cardiometabolic 
risk factors, preclinical atherosclerosis and type 2 diabetes mellitus (T2DM) during a 10-year follow-up in YFS. 
The prospective associations are shown as unadjusted (Model 1), adjusted for all baseline cardiometabolic risk 
factors shown in Table 1 (Model 2), and further adjusted for baseline serum steroid hormone binding globulin 
(SHBG) and oral contraceptive use in women. Open and closed squares and circles indicate P ≥ 0.05 and 
P < 0.05, respectively.
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the risk of developing T2DM. In some population and patient cohorts, observational cross-sectional associations 
between hArg and prevalent T2DM were absent6, 7, 18, whereas in some studies, T2DM was associated with lower 
hArg levels compared to non-diabetic controls8, and, in patients with T2DM undergoing maintenance haemodi-
alysis, low hArg levels correlated with longer duration of T2DM1.
No independent associations were observed between hArg and 6-year incident high-risk carotid intima-media 
thickness or carotid distensibility. Neither was the baseline hArg associated with the presence of coronary artery 
calcification assessed seven years after the hArg quantification. These results are consistent with the lack of a 
cross-sectional association of hArg with coronary calcium in the population-based Dallas Heart Study8. In addi-
tion, there were no associations between genetically determined hArg and CAD or myocardial infarction, sug-
gesting that serum hArg does not have a causal effect on the development of coronary atherosclerosis or its 
clinical manifestations in humans, at least at concentrations normally observed in the circulation. This is in line 
with the lack of a cross-sectional association between hArg and prevalent CAD in over 3000 patients referred for 
coronary angiography18 as well as with the absence of associations between baseline hArg and future cardiovas-
cular events and myocardial infarction in haemodialysis patients2. The experimental evidence on the role of hArg 
in atherosclerosis is not conclusive, as one study showed that hArg augments the osteo-/chondrogenic transfor-
mation of human aortic vascular smooth muscle cells and aortic calcification9, whereas another study reported a 
beneficial role of hArg in balloon-injured rat carotids trough the inhibition of neointimal formation19.
There are no earlier systematic studies investigating the causal role of hArg in the regulation of serum metabo-
lite profiles. In our analysis, we found no evidence for causal relationships between circulating hArg and 122 sys-
temic metabolite measures. There are several potential explanations for this. Firstly, it is possible that hArg is an 
innocent AGAT metabolite and, at best, a biomarker with no direct causal effects on systemic metabolic pathways 
or diseases. This view is supported by experiments in rats and pigs, showing that >95% of orally administered 
Figure 4. Combined causal effect estimates (β = beta, odds ratio and 95% CI confidence intervals) of hArg with 
cardiometabolic risk factors, type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). For each 
metabolite, the summary-level data across the three hArg-associated SNPs (GATM rs1153858, CPS1 rs1047891 
and AGXT2 rs37369) was combined using weighted linear regression, and the heterogeneity in the causal effects 
from different individual variants was tested by Cochran’s Q statistic. All p-values for combined causal effects 
>0.05. A p-value of >0.05 from Cochran’s Q statistic indicates that there is no more heterogeneity between 
causal effects estimated using the variants individually than would be expected by chance.
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hArg was recovered in urine and not metabolized in tissues20. Moreover, the RCT on oral hArg supplementation 
in 20 young volunteers did not detect any systemic effects, with the exception of a moderate increase in blood glu-
cose, despite a 7-fold increase in plasma hArg compared to placebo15. Secondly, hArg may have specific effects on 
metabolic pathways not covered by the metabolomics platform used or may play a more important role in certain 
pathologies rather than in healthy individuals.
The use of oral oestrogen contraceptives in young women was associated with a marked increase in hArg 
levels. A previous study of pregnant YFS participants reported that hArg levels were increased during the second 
and third trimesters of normal pregnancy when compared to non-pregnant women and that hArg was positively 
correlated with gestational age21. The gradual increase in hArg levels during normal pregnancy is likely due to 
a parallel increase in maternal oestrogen levels. This reasoning is supported by experiments showing that the 
expression of the AGAT gene is modulated by oestrogen in chick liver22 and consistent with a marked increase in 
the renal AGAT mRNA and protein expression of pregnant spiny mice at term when compared to non-pregnant 
animals23. The fact that the hArg synthesis by AGAT is modulated by sex hormones might aid to explain the 
observed sex differences in the associations between hArg and incident cardiometabolic risk factors and T2DM. 
This hypothesis warrants further examination.
Our study has limitations that are general to all MR studies, and these should be considered when interpreting 
the results. The three MR assumptions in the context of the present study are as follows: 1) the genetic variants 
should be associated with the circulating hArg levels, 2) they should affect the outcome only through the cir-
culating hArg levels (exclusion restriction assumption), and 3) they should be independent of hArg-outcome 
confounders (independence assumption). Regarding the first assumption, we acknowledge that the sample size 
used to quantify the strength of the SNP–hArg associations is limited (n = 5143). On the other hand, the lead 
Figure 5. Combined causal effect estimates (β = beta; coloured bars indicate the direction and magnitude of the 
effect; yellow bars, β > 0, blue bars, β < 0) of hArg with 122 systemic metabolic measures using summary-level 
data from previous meta-analyses of genome-wide association studies. For each metabolite, the summary-level 
data across the three hArg associated SNPs (GATM rs1153858, CPS1 rs1047891 and AGXT2 rs37369) was 
combined using weighted linear regression, and the heterogeneity in the causal effects from different individual 
variants was tested by Cochran’s Q statistic. All p-values for combined causal effects >0.05. A p-value of >0.05 
from Cochran’s Q statistic indicates that there is no more heterogeneity between causal effects estimated using 
the variants individually than would be expected by chance. The numbers of individuals used to estimate SNP–
metabolite associations vary between 8 905 and 24 924, depending on the metabolite.
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GATM variant is a strong instrument for MR analyses, explaining ~5.3% of the variability in serum hArg levels in 
YFS, and all three variants included in the MR analyses showed genome-wide significant (P < 5 × 10−8, F-statistic 
>120, Table S2) associations with serum hArg levels in the original GWAS24. In addition, the statistical power 
in two-sample MR analyses is mainly determined by the number of individuals used to assess SNP–outcome 
associations25, for which we used publicly available summary statistics from large consortiums involving tens 
to hundreds of thousands of individuals. An adequate statistical power to detect causal effects is evident by the 
inspection of the 95% confidence intervals for, e.g., BMI-adjusted waist circumference in Fig. 4 showing that the 
confidence intervals for the combined causal estimates are comparable to those from the observational associ-
ation analyses when there is no heterogeneity between the causal estimates. Moreover, some degree of sample 
overlap between individuals used to estimate SNP–hArg and SNP–outcome associations is present for some of 
the outcomes studied; however, the possible effect of this sample overlap on the causal estimates is likely to be 
small, because the individuals used in the hArg GWAS constitute a very small proportion of the total number of 
individuals used in the large meta-analyses of GWASs on outcomes. The risk that the independence assumption 
is violated due to a population stratification in GWASs is minimized by adjustments for principal components. 
Another potential concern in our MR analyses, as in all MR studies, is a horizontal pleiotropy (i.e. the genetic 
variants affect the outcome through pathways not mediated by hArg levels). We could avoid too precise causal 
estimates in the cases in which some of the genetic variants showed a pleiotropic effect on outcome by using 
weighted linear regression, and formally tested the presence of heterogeneity between the causal estimates using 
Cochran’s Q statistic. Moreover, the three genome-wide significant hArg-related SNPs used to estimate causal 
effects have biologically plausible and functional roles in the endogenous hArg synthesis and/or catabolism as 
illustrated in Figures S6 and S7. Finally, despite single-variant pleiotropy in some SNP–outcome associations, the 
other two of the three independent variants showed not even a weak association with the outcome (Tables S1 and 
S3–S7). As discussed before26, although both negative and positive results are potentially subject to a violation of 
the assumptions required for MR, in the case of negative results, the biases would have to balance out perfectly 
to result in an effect estimate of zero when there is in fact a true effect, making negative findings from MR more 
reliable than positive ones.
In the observational analyses, the 10-year follow-up was not long enough to investigate very long term predic-
tive value of hArg on studied cardiometabolic outcomes. However, we observed a significant association between 
baseline hArg and new onset T2DM in young women indicating that the follow-up period was sufficiently long 
to detect such associations despite limited number of new-onset cases of T2DM. Furthermore, the follow-up 
period of 6 years used to study the association between hArg and high-risk carotid atherosclerosis is relatively 
short. However, traditional cardiometabolic risk factors were associated with these outcomes suggesting that the 
follow-up time was long enough to detect such association also with hArg.
In conclusion, our results show that circulating hArg is not causally associated with various cardiometabolic 
risk factors, the systemic metabolic profile, T2DM or CAD. Our results do not provide any consistent evidence 
that interventions aimed at modifying hArg levels will improve the metabolic profiles or risk of T2DM or CAD. 
Whether hArg could be used as a biomarker to predict future abdominal obesity in young men remains to be 
investigated in future studies.
Methods
Study population and data sources. YFS is a Finnish longitudinal population study on the evolution of 
cardiovascular risk factors from childhood to adulthood27. The study began in 1980, when 3,596 children and 
adolescents aged 3–18 years were randomly selected from five university hospital catchment areas in Finland. 
In 2001, 2,288 participants aged 24–39 years attended the 21-year follow-up. We excluded 33 pregnant women, 
as their hArg levels have been shown to be elevated during pregnancy in the YFS21, as well as 11 subjects who 
had type 1 diabetes at baseline and one participant who had an exceptionally high hArg serum concentration 
(20.2 µmol/L) from all analyses. Therefore, 2,106 participants contributed to the cross-sectional association anal-
ysis of hArg and cardiometabolic risk factors at baseline (in 2001). We considered the participants of the lon-
gitudinal analyses who attended the 2001 follow-up and at least one later follow-up in 2007 or 2011. Of these 
participants, we included those for whom hArg and covariate data at the 2001 follow-up (used as baseline for the 
present study) and cardiometabolic risk factor data at the 2007 and/or 2011 follow-up were available and who 
were not pregnant in 2001 (n = 1801). The YFS was approved by the 1st ethical committee of the Hospital District 
of Southwest Finland (on September 21st, 2010) and by local ethical committees. The methods were carried out in 
accordance with the relevant guidelines and regulations. The participants gave written informed consent.
Genetic instrument selection for Mendelian randomization (MR) studies. For MR analyses, we 
used three single-nucleotide polymorphisms (SNPs) – GATM (glycine amidinotransferase) rs1153858, CPS1 
(carbamoyl-phosphate synthase 1) rs1047891 (formerly rs7422339), and AGXT2 (alanine-glyoxylate ami-
notransferase 2) rs37369 – that were all associated with serum hArg levels on a genome-wide significance level 
(P < 5 × 10−8) in a recent genome-wide association study (GWAS) of 5,143 individuals24. The GATM rs1153858 
variant alone, also associated with GATM mRNA expression in a tissue-specific manner (see Figure S6), explained 
~5.3% of the variability in serum hArg levels in the YFS24. The summary statistics for the SNP-outcome associa-
tions were extracted from the summary-level data available in the public domain from large GWASs (see number 
of subjects in Fig. 1) investigating the associations of gene variants with conventional cardiometabolic risk factors, 
including BMI28, 29, waist circumference30, fasting glucose31, fasting insulin31, HbA1c32, proinsulin33, total choles-
terol34, high-density lipoprotein (HDL) cholesterol34, triglycerides34, low-density lipoprotein (LDL) cholesterol34 
as well as CAD35, 36 and T2DM37. The summary-level data for 122 NMR-method-based serum metabolites from 
the MAGNETIC NMR GWAS consortium38 were downloaded from http://computationalmedicine.fi/data. All 
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associations extracted from the summary-level data on hArg-related variants and outcomes are presented in 
Tables S1–S7.
Serum hArg measurements and other biochemical assays. HArg was measured in serum stored at 
−80 °C by means of reversed-phase high-performance liquid chromatography at the Clinical Institute of Medical 
and Chemical Laboratory Diagnostics, Medical University of Graz39. Details of the biochemical measurements 
and clinical data are presented in Supplementary Methods.
Metabolic profiling. High-throughput NMR spectroscopy was used for the absolute quantification of serum 
metabolites. The metabolite set (includes 228 quantified metabolites) covers multiple metabolic pathways, includ-
ing lipoprotein lipids and subclasses, fatty acids and fatty acid compositions, as well as amino acids and glycolysis 
precursors. All molecular measures are quantified in a single experimental setup, constituting both established 
and novel metabolic risk factors. This NMR-based metabolite profiling has previously been used in various epide-
miological40, 41 and genetic studies38 and has been reviewed recently42. Details of the experimentation have been 
described elsewhere42, 43.
Incident outcome definitions for the studied traits. In the YFS, the metabolic syndrome components 
were defined according to harmonized criteria11: waist circumference ≥102 cm in males and ≥88 cm in females 
(1), hypertriglyceridemia >1.7 mmol/l (2), HDL cholesterol <1.0 mmol/l in males and <1.3 mmol/l in females 
(3), blood pressure ≥130/85 mmHg or treatment for blood pressure (4), and fasting plasma glucose ≥5.6 mmol/l 
or previously diagnosed T2DM. High insulin was defined as a 10-year fasting insulin in the >90th percentile 
using sex-specific values corresponding with a fasting insulin of ≥18.8 IU/L for men and ≥15.2 IU/L for women. 
Obesity was defined as BMI ≥30 kg/m2. In 2008, cardiac computed tomography was performed to measure coro-
nary artery calcification (CAC) for a subsample of 589 participants then aged 40–46 years44. The absence of CAC 
was defined as an Agatston score of 0, and individuals with an Agatston score of 1 or greater were classified as 
having CAC. In 2001 and 2007, carotid artery intima-media thickness (IMT) and distensibility were measured 
as described in detail previously45, 46. As previously47, high-risk carotid IMT and distensibility were defined as 
falling within the age- and sex-specific ≥90 percentile and ≤10 percentile, respectively. Participants were clas-
sified as having T2DM if they had fasting a plasma glucose level of 7.0 mmol/l or greater, reported the use of 
oral glucose-lowering medication or insulin but had not reported having type 1 diabetes mellitus, or reported a 
diagnosis of T2DM by a physician. Participants were also classified as having T2DM if they had HbA1c ≥6.5% 
(48 mmol/mol).
Statistical Methods. All statistical analyses were conducted with R version >3.1.2 (https://www.r-project.org/).
Clinical determinants of hArg levels in YFS. We used linear regression analysis to explore the associa-
tions of hArg with common cardiovascular risk factors at baseline (age, sex, LDL cholesterol, HDL cholesterol, 
triglycerides, systolic and diastolic blood pressure, CRP, glucose, insulin, BMI, waist circumference, smoking and 
family history of CAD) as well as serum sex hormone-binding globulin (SHBG) and hormonal oral contraceptive 
use in women. Stepwise model selection by Akaike’s information criterion (AIC) was performed to determine the 
most important determinants of hArg levels using the stepAIC R function.
Cross-sectional association analyses of hArg and metabolites in YFS. To facilitate the 
log-transformation, zero values in NMR-based metabolic measures were replaced by half of the minimum posi-
tive value found for each metabolite, assuming this to be the best estimation of detection limit. Prior to statistical 
analyses, NMR-based metabolic measures were log-transformed and scaled to standard deviations (SD) to facil-
itate comparisons across metabolites. Association magnitudes are reported in SD units of metabolite concentra-
tion per 1-SD increment in log-transformed hArg. For sex-stratified cross-sectional analysis, sex-specific scaling 
was applied for NMR metabolites. Due to the correlated nature of the systemic metabolite measures, over 95% of 
the variation in the metabolic data was explained by 25 principal components, and a P-value of 0.05/25 = 0.002 
was thus required after multiple testing correction40.
Cross-sectional and longitudinal associations of baseline hArg with circulating metabolites at baseline and at 
the follow-ups were analysed using linear regression models, stratified by sex, with each metabolic measure as the 
outcome and hArg as the explanatory variable. The regression models were adjusted for age, BMI, daily smoking, 
serum SHBG and oral contraceptive use (in women). For each metabolic measure, the sex-related differences 
in observational estimates were tested by using the Z-statistic. Interactions between BMI and each metabolite 
measure in relation to hArg levels were tested in men and women separately by adding the interaction term to the 
linear regression models.
Longitudinal association analyses of hArg with cardiometabolic risk factors, preclinical ath-
erosclerosis and T2DM in YFS. The prospective associations of hArg with 6- or 10-year incident Mets 
components, high insulin (see incident outcome definitions above), and incident obesity (BMI >30 kg/m2) were 
assessed using logistic regression models with scaled log-transformed baseline hArg as an explanatory variable. 
Incident T2DM during the 10-year follow-up was used as an outcome variable to assess the prospective associa-
tion of hArg with T2DM. The follow-up period for carotid artery ultrasound parameters was six years. Coronary 
calcification was assessed once seven years after the baseline in 2008. Those with the condition at baseline were 
excluded from the analysis. We fitted unadjusted models (Model 1) and models that were adjusted for all cardi-
ometabolic risk factors shown in Table 1 (Model 2) and, further, for serum SHBG and oral contraceptive use (in 
women, Model 3).
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Instrumental variable analyses using publicly available summary-level data on hArg, metabo-
lites, cardiometabolic traits, T2DM and CAD. The strengths of the genetic instruments used for hArg 
were assessed based on the F-statistic derived from the summary statistics of the hArg GWAS (Table S2). Despite 
the relatively small sample size (n = 5143) in the meta-analysis of GWASs on hArg24, all F-statistics for the instru-
ments were well over 10 (between 120 and 370) (Table S2), indicating that all three instruments separately are 
sufficiently strong to be used in MR studies. We then used these instruments in the Mendelian randomization 
(MR) analyses to quantify the strengths of the causal associations of hArg with NMR metabolites, cardiometa-
bolic traits, T2DM and CAD. As previously48, to evaluate combined causal estimates with 95% confidence inter-
vals (95% CI) from summary statistics of the three independent SNPs, we performed a weighted linear regression 
of the genetic associations with each outcome variable on the genetic associations with hArg using first-order 
weights described in more detail with an R code implementation elsewhere49. This multiplicative random-effects 
model was used for combining causal estimates to obtain the same point estimate as from a fixed-effects model 
while avoiding too precise estimates in the case of heterogeneity in the causal effects obtained from different 
genetic variants. The combined MR estimates are in units of 1-unit increment of a continuous outcome (or odds 
ratio of disease risk) per 1-µmol/L increment in hArg. We performed heterogeneity tests based on Cochran’s Q 
statistic to detect potential dissimilarity between the causal effects across the hArg SNPs (instrumental variables).
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